AVR (AVR) Stock Analysis
Verdict: AVOID
Severe cash burn ($79.8M FCF/yr) against $12.6M cash creates imminent dilution risk, overriding early-stage TAVR technology potential.
Investment score: 20/100
Is AVR Stock Worth Reviewing? AI Model Thesis
The model evaluates Anteris Technologies as a high-risk speculative asset due to severe cash runway exhaustion ($12.58M cash vs $79.76M annual burn) and negative total equity, despite clinical promise in its DurAVR heart valve.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| IART | -138.77 | 0.95 | 0.60 | 11.34 | — | -0.00 |
| PRCT | -8.87 | 2.86 | 2.90 | -8.38 | — | -0.33 |
| CBLL | -13.37 | 6.98 | 8.76 | -13.99 | — | -0.65 |
| SIBN | -53.44 | 4.40 | 3.77 | -155.95 | — | -0.07 |
| VREX | 35.24 | 1.57 | 0.90 | 12.12 | — | 0.03 |
Should You Buy or Sell AVR Stock? Model Reasoning
The model arrives at an AVOID recommendation driven by critical liquidity risk and extreme financial leverage. Anteris reported $12.58M in cash as of Dec 31, 2025, against an annual free cash flow burn of $79.76M, leaving approximately 1.9 months of runway without substantial dilutive financing. Furthermore, 2025 net losses of $94.14M on revenue of just $1.91M resulted in negative stockholders' equity (-$93,000), while major insider L1 Capital aggressively reduced its stake by over 2.5M shares in Q3 2026.
AVR Fair Value & Price Target — AI Valuation
- Model Assumptions: ["High likelihood of 30-50% equity dilution in 2026/2027 to cover -$79.8M annual FCF burn.","DurAVR valve achieves regulatory approval by 2028 and hits analyst consensus revenue of $120M by 2029.","Long-term clinical adoption achieves 20%+ operating margins post-2029."]
AVR Risk & Opportunity Analysis
Key Investment Risks
- Imminent Equity Dilution and Cash Runway Exhaustion — With $12.58M cash remaining against a -$79.76M annual FCF burn, the company must issue equity or convertible debt immediately, drastically diluting existing shareholders before Dec 31, 2026.
- Severe Balance Sheet Distress and Insolvency Exposure — Negative stockholders' equity (-$93,000) in 2025 combined with -$94.14M net income creates default risks on trade payables ($21.37M current liabilities vs $15.68M current assets).
- Persistent Institutional and Insider Liquidation — Key institutional holder L1 Capital sold over 2.5 million shares in July-August 2026 at prices between $8.04 and $9.30, exerting ongoing overhead selling pressure.
- Ongoing Clinical Trial Cost Overruns and Negative Surprises — A 4-quarter streak of EPS misses (Q2 2026 EPS of -$0.30 vs -$0.21 consensus) highlights recurring clinical trial cost overruns and operational delays.
Growth Opportunities & Upside Drivers
- DurAVR Novel Biomimetic TAVR Valve Design — DurAVR mimics human aortic valve hemodynamics, addressing a global TAVR market projected to exceed $10B, offering significant licensing or acquisition value if pivotal trial data succeeds by 2027.
- Proprietary ADAPT Anti-Calcification Tissue Platform — ADAPT tissue treats bovine pericardium to reduce calcification, providing superior bio-prosthetic longevity compared to existing standard-of-care valves.
- Long-Term Revenue Acceleration Forecast — Consensus estimates project revenue scaling from $10M in 2027 to $120M in 2029 as regulatory approvals expand across global jurisdictions.
- Unanimous Wall Street Analyst Target Upside — Analyst consensus target of $18.00 implies 127.6% upside from the current price of $7.91, supported by continued Overweight ratings from Cantor Fitzgerald and Barclays.
AVR Action Plan — Entry, Exit and Stop Loss from the Model View
moderate
aggressive
conservative
Frequently Asked Questions About AVR (AVR)
Is AVR stock a good investment?
The cached TradeMates AI model rates AVR as AVOID with an investment score of 20/100. The model evaluates Anteris Technologies as a high-risk speculative asset due to severe cash runway exhaustion ($12.58M cash vs $79.76M annual burn) and negative total equity, despite clinical promise in its DurAVR heart valve. This is algorithmic model output, not personal investment advice.
Does AVR pay a dividend?
The cached stock data on this page does not show a positive dividend yield for AVR. Dividend status can change, so verify the latest company filings before relying on income assumptions.
What does AVR stock do?
Pre-commercial clinical-stage structural heart medical device developer focusing on the DurAVR transcatheter heart valve system while generating minimal legacy revenue from ADAPT tissue bioscaffolds.
What is AVR stock's price target?
This cached page does not contain a precise model fair value for AVR.
Is AVR stock a buy?
The TradeMates model verdict for AVR is AVOID with an investment score of 20/100. Treat this as a model signal to review, not a personal buy recommendation.
Is AVR a good dividend stock?
AVR is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.